Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans-Reference-Cited by-同舟云学术

Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans

Published:2010-08-10 Issue:11 Volume:38 Page:2023-2031
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Shilling Adam D.,Nedza Frank M.,Emm Thomas,Diamond Sharon,McKeever Edward,Punwani Naresh,Williams William,Arvanitis Argyrios,Galya Laurine G.,Li Mei,Shepard Stacey,Rodgers James,Yue Tai-Yuen,Yeleswaram Swamy

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference15 articles.

1. Drug Metabolites in Safety Testing

2. The Use of BDDCS in Classifying the Permeability of Marketed Drugs

3. Janus kinases in immune cell signaling

4. Determination of mean valproic acid serum level by assay of a single pooled sample

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ruxolitinib as a CaMKII inhibitor for treatment of cardiac arrhythmias: Applications and prospects;Heart Rhythm;2024-08

2. A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors;EMBO Molecular Medicine;2024-03-06

3. JAK Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08

4. Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib;Pharmaceuticals;2023-07-07

5. An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor;Science Translational Medicine;2023-06-21